Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms RISE
- Sponsors Teva Branded Pharmaceutical Products R&D
- 06 Apr 2024 According to aTeva Pharmaceutical Industries media release, the new data from this trial presented at the 2024 Congress of the Schizophrenia International Research Society (SIRS) taking place from April 3-7, 2024 in Florence, Italy.
- 01 Nov 2023 According to a Teva Pharmaceutical Industries media release, company announced the publication of efficacy and safety findings this study Risperidone Subcutaneous Extended-Release (RISE) study in The Lancet Psychiatry.
- 01 Nov 2023 Results presented in a Teva Pharmaceutical Industries media release.